Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer (Q29620902)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer (English)

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Marina Garassino

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

9

Everett E Vokes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

8

Adam Pluzanski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Julie Brahmer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Paul Baas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Lucio Crinò

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Wilfried E E Eberhardt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Elena Poddubskaya

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Scott Antonia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Esther Holgado

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

David Waterhouse

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Neal Ready

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Justin Gainor

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Osvaldo Arén Frontera

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Libor Havel

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Martin Steins

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Joachim G Aerts

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Manuel Domine

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Luis Paz-Ares

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Martin Reck

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Christine Baudelet

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Christopher T Harbison

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Brian Lestini

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

David R Spigel

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

16 February 2020

language of work or name

1 reference

30 April 2017

publication date

31 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

The New England Journal of Medicine

16 February 2020

published in

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

373

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

123-135

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

2

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

16 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

The blockade of immune checkpoints in cancer immunotherapy

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Programmed death ligand-1 expression in non-small cell lung cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4681400

26 November 2018

Pathology of lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26028407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26028407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1504627

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

3 references

30 April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028407%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

3 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=26028407

30 April 2017